NBIX
Neurocrine Biosciences, Inc.
NBIX has the edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR
Oscar Health, Inc.
OSCR's outlook is improving, though it still trails on the overall score.
NBIX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NBIX's revenue, profitability, cash flow and balance sheet are all currently strong.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NBIX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $169 | — |
| Cheap | 25x | $169 | -0.3% |
| Current | 25x | $169 | — |
| Fair | 44x | $297 | +75% |
| Expensive | 145x | $981 | +479% |
Historical ranges are pointers, not guarantees.
NBIX's PE is in its cheap range at 25x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over NBIX in the historical PE scenario, which offers more potential upside but is not a forecast.
NBIX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for NBIX, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NBIX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.06 | +34% |
| Q3 2026 | $6.75 | +61% |
| Q2 2026 | $6.83 | +102% |
| Q1 2026 | $6.50 | +120% |
| Q4 2025 | $4.67 | +42% |
| Q3 2025 | $4.18 | +11% |
| Q2 2025 | $3.38 | +0.6% |
| Q1 2025 | $2.95 | -20% |
| Q4 2024 | $3.29 | +33% |
NBIX has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
NBIX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +41% |
| Q2 2026 | $959M | +39% |
| Q1 2026 | $814.5M | +42% |
| Q4 2025 | $805.5M | +28% |
| Q3 2025 | $794.9M | +28% |
| Q2 2025 | $687.5M | +16% |
| Q1 2025 | $572.6M | +11% |
| Q4 2024 | $627.7M | +22% |
NBIX's revenue has grown year over year for 21 quarters in a row: $1.1B last quarter, up 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -0.6 points |
| Q2 2026 | 16% | -5.4 points |
| Q1 2026 | 24% | +20 points |
| Q4 2025 | 26% | +3.6 points |
| Q3 2025 | 30% | +0.5 points |
| Q2 2025 | 21% | -3.5 points |
| Q1 2025 | 4.1% | -15 points |
| Q4 2024 | 23% | -6.6 points |
NBIX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NBIX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
NBIX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $383.6M | +79% |
| Q2 2026 | $128.6M | +44% |
| Q1 2026 | $136.7M | +153% |
| Q4 2025 | $390.8M | +66% |
| Q3 2025 | $214.3M | +43% |
| Q2 2025 | $89.5M | +69% |
| Q1 2025 | $54.1M | -55% |
| Q4 2024 | $235.2M | +99% |
NBIX has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
NBIX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +1M shares |
| 1 year | +2.6% | +2.7M shares |
| 3 years | +4.1% | +4.1M shares |
| 5 years | +7.7% | +7.5M shares |
| Available history | +8.2% | +8M shares |
NBIX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $92.1M |
| Q2 2026 | $12M |
| Q1 2026 | $54M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $17.7M |
| Q1 2025 | $150M |
NBIX spent $158M buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NBIX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
NBIX has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over NBIX on leverage, with a lower net debt burden relative to earnings.
NBIX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.7 | Neutral |
| Stochastic | 65.8 | Neutral |
NBIX's weekly RSI is 62 (neutral) and its Stochastic is 66 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NBIX PE vs Healthcare Sector
| Metric | NBIX | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 2.9% below |
| PE % | 17 | 29 | 12 pts below |
NBIX is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over NBIX on valuation relative to its sector.
NBIX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $147.8 | 15% above |
| 20 week MA | $156.4 | 8.3% above |
| 50 week MA | $147.5 | 15% above |
| 100 week MA | $138.4 | 22% above |
| 200 week MA | $128.9 | 31% above |
NBIX is in an uptrend: it's above all five of its weekly moving averages, and 31% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
NBIX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $108.4 | $97.7 | -9.9% |
| 2021 | $97.7 | $85.1 | -13% |
| 2022 | $85.1 | $120.3 | +41% |
| 2023 | $120.3 | $131.8 | +9.5% |
| 2024 | $131.8 | $139.4 | +5.8% |
| 2025 | $139.4 | $145.3 | +4.2% |
| 2026 YTD | $145.3 | $169.4 | +17% |
NBIX has finished higher in four of the last six years. It's up 17% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NBIX on returns for 2026, with the stronger performance.